1-2-6-7-tetraoxaspiro(7.11)nonadecane and Malaria

Malaria is a prevalent fatal disease in tropical and subtropical regions around the world. Combinations of Artemisinin, folate antagonists, quinolines, and antibiotics are major choices in clinics. Currently, wide range of parasite's resistance necessitates the search for chemical compounds with new structures and novel antimalarial targets. The literature review was performed covering the relevant literatures published from 1966 to 2021. On the basis of structural classification (spiro-peroxides, spiroindolones, spirocyclohexadienones et al.), different types of molecules were summarized with resources, anti-malarial activities, structure-activity relationship, target introductions, resistance, development progress, and synthetic strategies, for the purpose of providing comprehensive information for developing antimalarial drugs to overcome drug resistance and highlighting the importance of the spiral structure in medicinal chemistry.

Topics: Antimalarials; Drug Resistance; Folic Acid Antagonists; Humans; Malaria; Plasmodium falciparum; Quinolines

We have reported that two endoperoxides, N-89 and N-251, synthesized in 2001, possess potent antimalarial activities. Aiming at their eventual use for curing malaria in humans, we have been investigating various aspects of their antimalarial actions. Here we show that N-89 and N-251 inhibit the growth of Plasmodium falciparum within human erythrocytes in vitro at its lifecycle stage 'trophozoite' specifically. It is known that artemisinin compounds, which are currently used for curing malaria, have other stage-specificities. Therefore, it is likely that the antimalarial mechanism of N-89 and N-251 differs from those of artemisinin compounds. As malaria parasites resistant to artemisinin-based combination therapy are currently emerging in some tropical regions, N-89 and N-251 are candidates for overcoming these new problems.

Topics: Animals; Antimalarials; Artemisinins; Drug Resistance, Multiple; Erythrocytes; Heterocyclic Compounds, 2-Ring; Humans; Malaria; Parasitic Sensitivity Tests; Plasmodium falciparum; Spiro Compounds; Tetraoxanes; Trophozoites

Plasmodium falciparum, the major causative parasite for the disease, has acquired resistance to most of the antimalarial drugs used today, presenting an immediate need for new antimalarial drugs. Here, we report the in vitro and in vivo antimalarial activities of 6-(1,2,6,7-tetraoxaspiro[7.11]nonadec-4-yl)hexan-1-ol (N-251) against P. falciparum and Plasmodium berghei parasites. The N-251 showed high antimalarial potencies both in the in vitro and the in vivo tests (EC(50) 2.3×10(-8) M; ED(50) 15 mg/kg (per oral)). The potencies were similar to that of artemisinin in vitro and greater than artemisinin's activity in vivo (p.o.). In addition, N-251 has little toxicity: a single oral administration at 2000 mg/kg to a rat gave no health problems to it. Administration of N-251 to mice bearing 1% of parasitemia (per oral 68 mg/kg, 3 times a day for 3 consecutive days) resulted in a dramatic decrease in the parasitemia: all the 5 mice given N-251 were cured without any recurrence, with no diarrhea or weight loss occurring in the 60 days of experiment. N-251 deserves more extensive clinical evaluation, desirably including future trials in the human.

Topics: Administration, Oral; Animals; Antimalarials; Artemisinins; Cell Line, Tumor; Drug Therapy, Combination; Erythrocytes; Heterocyclic Compounds, 2-Ring; Hexanols; Humans; Malaria; Malaria, Falciparum; Mice; Mice, Inbred ICR; Molecular Structure; Parasitemia; Parasitic Sensitivity Tests; Plasmodium berghei; Plasmodium falciparum; Rats; Spiro Compounds; Survival Analysis; Tetraoxanes

CsOH- or Ag(2)O-mediated cycloalkylation of (alkylidene)bisperoxides 3 and 1,n-dihaloalkanes (n = 3-8) provided the corresponding medium-sized 1,2,4,5-tetraoxacycloalkanes 4-8 in moderate yields. Subsequent evaluation of the antimalarial activity of the cyclic peroxides 4-8 in vitro and in vivo revealed that 1,2,6,7-tetraoxaspiro[7.11]nonadecane 4a has considerable potential as a new, inexpensive, and potent antimalarial drug.

Topics: Animals; Antimalarials; Cesium; Cyclization; Drug Evaluation, Preclinical; Heterocyclic Compounds, 2-Ring; Hydroxides; Malaria; Mice; Oxides; Plasmodium berghei; Plasmodium falciparum; Silver Compounds; Spiro Compounds; Structure-Activity Relationship